APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Acute Myeloid Leukemia Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Acute Myeloid Leukemia Drugs Market Outlook and Growth Opportunities 2026

Report ID 173960360422 December 2025199 pages

Choose your research edition.

Industry ResearchAcute Myeloid Leukemia Drugs Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Acute Myeloid Leukemia Drugs Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Acute Myeloid Leukemia Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Acute Myeloid Leukemia Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Acute Myeloid Leukemia Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Acute Myeloid Leukemia Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Acute Myeloid Leukemia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Acute Myeloid Leukemia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Acute Myeloid Leukemia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Acute Myeloid Leukemia Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Acute Myeloid Leukemia Drugs market include Takeda Pharmaceuticals, Eisai, Novartis, Eli Lilly and Company, Sunesis Pharmaceuticals, Otsuka Holdings, Genzyme Corporation, Clavis Pharma and Cephalon, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Acute Myeloid Leukemia Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Acute Myeloid Leukemia Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Acute Myeloid Leukemia Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Acute Myeloid Leukemia Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Acute Myeloid Leukemia Drugs Segment by Company

Takeda Pharmaceuticals

Eisai

Novartis

Eli Lilly and Company

Sunesis Pharmaceuticals

Otsuka Holdings

Genzyme Corporation

Clavis Pharma

Cephalon

Bristol Myers Squibb

Ambit Biosciences Corporation

Acute Myeloid Leukemia Drugs Segment by Type

Chemotherapy

Targeted Therapy

Other

Acute Myeloid Leukemia Drugs Segment by Application

Hospital

Clinic

Others

Acute Myeloid Leukemia Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Acute Myeloid Leukemia Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Acute Myeloid Leukemia Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Acute Myeloid Leukemia Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Acute Myeloid Leukemia Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Myeloid Leukemia Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Acute Myeloid Leukemia Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Myeloid Leukemia Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Acute Myeloid Leukemia Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Acute Myeloid Leukemia Drugs industry.

Chapter 3: Detailed analysis of Acute Myeloid Leukemia Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Acute Myeloid Leukemia Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Acute Myeloid Leukemia Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Acute Myeloid Leukemia Drugs Industry Trends Table 2. Acute Myeloid Leukemia Drugs Industry Drivers Table 3. Acute Myeloid Leukemia Drugs Industry Opportunities and Challenges Table 4. Acute Myeloid Leukemia Drugs Industry Restraints Table 5. Global Acute Myeloid Leukemia Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Acute Myeloid Leukemia Drugs Revenue Share by Company (2021-2026) Table 7. Global Acute Myeloid Leukemia Drugs Sales Volume by Company (k units) & (2021-2026) Table 8. Global Acute Myeloid Leukemia Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Acute Myeloid Leukemia Drugs Average Price (US$/unit) of Company (2021-2026) Table 10. Global Acute Myeloid Leukemia Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Acute Myeloid Leukemia Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Acute Myeloid Leukemia Drugs Company, Product Type & Application Table 13. Global Acute Myeloid Leukemia Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Acute Myeloid Leukemia Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Chemotherapy Table 18. Significant Companies of Targeted Therapy Table 19. Significant Companies of Other Table 20. Global Acute Myeloid Leukemia Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Acute Myeloid Leukemia Drugs Sales Volume by Type (2021-2026) & (k units) Table 22. Global Acute Myeloid Leukemia Drugs Sales Volume by Type (2027-2032) & (k units) Table 23. Global Acute Myeloid Leukemia Drugs Sales Volume Share by Type (2021-2026) Table 24. Global Acute Myeloid Leukemia Drugs Sales Volume Share by Type (2027-2032) Table 25. Global Acute Myeloid Leukemia Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Acute Myeloid Leukemia Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Acute Myeloid Leukemia Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Acute Myeloid Leukemia Drugs Sales Value Share by Type (2021-2026) Table 29. Global Acute Myeloid Leukemia Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital Table 31. Significant Companies of Clinic Table 32. Significant Companies of Others Table 33. Global Acute Myeloid Leukemia Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Acute Myeloid Leukemia Drugs Sales Volume by Application (2021-2026) & (k units) Table 35. Global Acute Myeloid Leukemia Drugs Sales Volume by Application (2027-2032) & (k units) Table 36. Global Acute Myeloid Leukemia Drugs Sales Volume Share by Application (2021-2026) Table 37. Global Acute Myeloid Leukemia Drugs Sales Volume Share by Application (2027-2032) Table 38. Global Acute Myeloid Leukemia Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Acute Myeloid Leukemia Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Acute Myeloid Leukemia Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Acute Myeloid Leukemia Drugs Sales Value Share by Application (2021-2026) Table 42. Global Acute Myeloid Leukemia Drugs Sales Value Share by Application (2027-2032) Table 43. Global Acute Myeloid Leukemia Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Acute Myeloid Leukemia Drugs Sales by Region (2021-2026) & (k units) Table 45. Global Acute Myeloid Leukemia Drugs Sales Market Share by Region (2021-2026) Table 46. Global Acute Myeloid Leukemia Drugs Sales by Region (2027-2032) & (k units) Table 47. Global Acute Myeloid Leukemia Drugs Sales Market Share by Region (2027-2032) Table 48. Global Acute Myeloid Leukemia Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Acute Myeloid Leukemia Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Acute Myeloid Leukemia Drugs Sales Value Share by Region (2021-2026) Table 51. Global Acute Myeloid Leukemia Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Acute Myeloid Leukemia Drugs Sales Value Share by Region (2027-2032) Table 53. Global Acute Myeloid Leukemia Drugs Market Average Price (US$/unit) by Region (2021-2026) Table 54. Global Acute Myeloid Leukemia Drugs Market Average Price (US$/unit) by Region (2027-2032) Table 55. Global Acute Myeloid Leukemia Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Global Acute Myeloid Leukemia Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Acute Myeloid Leukemia Drugs Sales by Country (2021-2026) & (k units) Table 58. Global Acute Myeloid Leukemia Drugs Sales Market Share by Country (2021-2026) Table 59. Global Acute Myeloid Leukemia Drugs Sales by Country (2027-2032) & (k units) Table 60. Global Acute Myeloid Leukemia Drugs Sales Market Share by Country (2027-2032) Table 61. Global Acute Myeloid Leukemia Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Acute Myeloid Leukemia Drugs Sales Value Market Share by Country (2021-2026) Table 63. Global Acute Myeloid Leukemia Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Acute Myeloid Leukemia Drugs Sales Value Market Share by Country (2027-2032) Table 65. Takeda Pharmaceuticals Company Information Table 66. Takeda Pharmaceuticals Business Overview Table 67. Takeda Pharmaceuticals Acute Myeloid Leukemia Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. Takeda Pharmaceuticals Acute Myeloid Leukemia Drugs Product Portfolio Table 69. Takeda Pharmaceuticals Recent Development Table 70. Eisai Company Information Table 71. Eisai Business Overview Table 72. Eisai Acute Myeloid Leukemia Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Eisai Acute Myeloid Leukemia Drugs Product Portfolio Table 74. Eisai Recent Development Table 75. Novartis Company Information Table 76. Novartis Business Overview Table 77. Novartis Acute Myeloid Leukemia Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Novartis Acute Myeloid Leukemia Drugs Product Portfolio Table 79. Novartis Recent Development Table 80. Eli Lilly and Company Company Information Table 81. Eli Lilly and Company Business Overview Table 82. Eli Lilly and Company Acute Myeloid Leukemia Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Eli Lilly and Company Acute Myeloid Leukemia Drugs Product Portfolio Table 84. Eli Lilly and Company Recent Development Table 85. Sunesis Pharmaceuticals Company Information Table 86. Sunesis Pharmaceuticals Business Overview Table 87. Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Product Portfolio Table 89. Sunesis Pharmaceuticals Recent Development Table 90. Otsuka Holdings Company Information Table 91. Otsuka Holdings Business Overview Table 92. Otsuka Holdings Acute Myeloid Leukemia Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Otsuka Holdings Acute Myeloid Leukemia Drugs Product Portfolio Table 94. Otsuka Holdings Recent Development Table 95. Genzyme Corporation Company Information Table 96. Genzyme Corporation Business Overview Table 97. Genzyme Corporation Acute Myeloid Leukemia Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Genzyme Corporation Acute Myeloid Leukemia Drugs Product Portfolio Table 99. Genzyme Corporation Recent Development Table 100. Clavis Pharma Company Information Table 101. Clavis Pharma Business Overview Table 102. Clavis Pharma Acute Myeloid Leukemia Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Clavis Pharma Acute Myeloid Leukemia Drugs Product Portfolio Table 104. Clavis Pharma Recent Development Table 105. Cephalon Company Information Table 106. Cephalon Business Overview Table 107. Cephalon Acute Myeloid Leukemia Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. Cephalon Acute Myeloid Leukemia Drugs Product Portfolio Table 109. Cephalon Recent Development Table 110. Bristol Myers Squibb Company Information Table 111. Bristol Myers Squibb Business Overview Table 112. Bristol Myers Squibb Acute Myeloid Leukemia Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. Bristol Myers Squibb Acute Myeloid Leukemia Drugs Product Portfolio Table 114. Bristol Myers Squibb Recent Development Table 115. Ambit Biosciences Corporation Company Information Table 116. Ambit Biosciences Corporation Business Overview Table 117. Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Product Portfolio Table 119. Ambit Biosciences Corporation Recent Development Table 120. Key Raw Materials Table 121. Raw Materials Key Suppliers Table 122. Acute Myeloid Leukemia Drugs Distributors List Table 123. Acute Myeloid Leukemia Drugs Customers List Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Acute Myeloid Leukemia Drugs Product Image Figure 2. Global Acute Myeloid Leukemia Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Acute Myeloid Leukemia Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Acute Myeloid Leukemia Drugs Sales (2021-2032) & (k units) Figure 5. Global Acute Myeloid Leukemia Drugs Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Acute Myeloid Leukemia Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Chemotherapy Image Figure 10. Targeted Therapy Image Figure 11. Other Image Figure 12. Global Acute Myeloid Leukemia Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Acute Myeloid Leukemia Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Acute Myeloid Leukemia Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global Acute Myeloid Leukemia Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Acute Myeloid Leukemia Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Acute Myeloid Leukemia Drugs Sales Value Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Others Image Figure 21. Global Acute Myeloid Leukemia Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Acute Myeloid Leukemia Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Acute Myeloid Leukemia Drugs Sales Volume Share by Application (2021-2032) Figure 24. Global Acute Myeloid Leukemia Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Acute Myeloid Leukemia Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Acute Myeloid Leukemia Drugs Sales Value Share by Application (2021-2032) Figure 27. Global Acute Myeloid Leukemia Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 28. Global Acute Myeloid Leukemia Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Acute Myeloid Leukemia Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Acute Myeloid Leukemia Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Acute Myeloid Leukemia Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. North America Acute Myeloid Leukemia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Acute Myeloid Leukemia Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Acute Myeloid Leukemia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Acute Myeloid Leukemia Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Acute Myeloid Leukemia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Acute Myeloid Leukemia Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. South America Acute Myeloid Leukemia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Acute Myeloid Leukemia Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Acute Myeloid Leukemia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Acute Myeloid Leukemia Drugs Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Acute Myeloid Leukemia Drugs Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Chemotherapy
  • Targeted Therapy
  • Other
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Takeda Pharmaceuticals
  • Eisai
  • Novartis
  • Eli Lilly and Company
  • Sunesis Pharmaceuticals
  • Otsuka Holdings
  • Genzyme Corporation
  • Clavis Pharma
  • Cephalon
  • Bristol Myers Squibb
  • Ambit Biosciences Corporation

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Acute Myeloid Leukemia Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Acute Myeloid Leukemia Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Acute Myeloid Leukemia Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Acute Myeloid Leukemia Drugs Market Dynamics
  1. 2.1 Acute Myeloid Leukemia Drugs Industry Trends
  2. 2.2 Acute Myeloid Leukemia Drugs Industry Drivers
  3. 2.3 Acute Myeloid Leukemia Drugs Industry Opportunities and Challenges
  4. 2.4 Acute Myeloid Leukemia Drugs Industry Restraints
3 Acute Myeloid Leukemia Drugs Market by Company
  1. 3.1 Global Acute Myeloid Leukemia Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Acute Myeloid Leukemia Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Acute Myeloid Leukemia Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Acute Myeloid Leukemia Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Acute Myeloid Leukemia Drugs Company Ranking (2024-2026)
  6. 3.6 Global Acute Myeloid Leukemia Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Acute Myeloid Leukemia Drugs Company Product Type and Application
  8. 3.8 Global Acute Myeloid Leukemia Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Acute Myeloid Leukemia Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Acute Myeloid Leukemia Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Acute Myeloid Leukemia Drugs Market by Type
  1. 4.1 Acute Myeloid Leukemia Drugs Type Introduction
  2. 4.1.1 Chemotherapy
  3. 4.1.2 Targeted Therapy
  4. 4.1.3 Other
  5. 4.2 Global Acute Myeloid Leukemia Drugs Sales Volume by Type
  6. 4.2.1 Global Acute Myeloid Leukemia Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Acute Myeloid Leukemia Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Acute Myeloid Leukemia Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Acute Myeloid Leukemia Drugs Sales Value by Type
  10. 4.3.1 Global Acute Myeloid Leukemia Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Acute Myeloid Leukemia Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Acute Myeloid Leukemia Drugs Sales Value Share by Type (2021-2032)
5 Acute Myeloid Leukemia Drugs Market by Application
  1. 5.1 Acute Myeloid Leukemia Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Acute Myeloid Leukemia Drugs Sales Volume by Application
  6. 5.2.1 Global Acute Myeloid Leukemia Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Acute Myeloid Leukemia Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Acute Myeloid Leukemia Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Acute Myeloid Leukemia Drugs Sales Value by Application
  10. 5.3.1 Global Acute Myeloid Leukemia Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Acute Myeloid Leukemia Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Acute Myeloid Leukemia Drugs Sales Value Share by Application (2021-2032)
6 Acute Myeloid Leukemia Drugs Regional Sales and Value Analysis
  1. 6.1 Global Acute Myeloid Leukemia Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Acute Myeloid Leukemia Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Acute Myeloid Leukemia Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Acute Myeloid Leukemia Drugs Sales by Region (2027-2032)
  5. 6.3 Global Acute Myeloid Leukemia Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Acute Myeloid Leukemia Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Acute Myeloid Leukemia Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Acute Myeloid Leukemia Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Acute Myeloid Leukemia Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Acute Myeloid Leukemia Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Acute Myeloid Leukemia Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Acute Myeloid Leukemia Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Acute Myeloid Leukemia Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Acute Myeloid Leukemia Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Acute Myeloid Leukemia Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Acute Myeloid Leukemia Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Acute Myeloid Leukemia Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Acute Myeloid Leukemia Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Acute Myeloid Leukemia Drugs Sales Value Share by Country, 2025 VS 2032
7 Acute Myeloid Leukemia Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Acute Myeloid Leukemia Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Acute Myeloid Leukemia Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Acute Myeloid Leukemia Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Acute Myeloid Leukemia Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Acute Myeloid Leukemia Drugs Sales by Country (2027-2032)
  6. 7.4 Global Acute Myeloid Leukemia Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Acute Myeloid Leukemia Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Acute Myeloid Leukemia Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Acute Myeloid Leukemia Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Acute Myeloid Leukemia Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Acute Myeloid Leukemia Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceuticals
  2. 8.1.1 Takeda Pharmaceuticals Company Information
  3. 8.1.2 Takeda Pharmaceuticals Business Overview
  4. 8.1.3 Takeda Pharmaceuticals Acute Myeloid Leukemia Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceuticals Acute Myeloid Leukemia Drugs Product Portfolio
  6. 8.1.5 Takeda Pharmaceuticals Recent Developments
  7. 8.2 Eisai
  8. 8.2.1 Eisai Company Information
  9. 8.2.2 Eisai Business Overview
  10. 8.2.3 Eisai Acute Myeloid Leukemia Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Eisai Acute Myeloid Leukemia Drugs Product Portfolio
  12. 8.2.5 Eisai Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Acute Myeloid Leukemia Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Acute Myeloid Leukemia Drugs Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Eli Lilly and Company
  20. 8.4.1 Eli Lilly and Company Company Information
  21. 8.4.2 Eli Lilly and Company Business Overview
  22. 8.4.3 Eli Lilly and Company Acute Myeloid Leukemia Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly and Company Acute Myeloid Leukemia Drugs Product Portfolio
  24. 8.4.5 Eli Lilly and Company Recent Developments
  25. 8.5 Sunesis Pharmaceuticals
  26. 8.5.1 Sunesis Pharmaceuticals Company Information
  27. 8.5.2 Sunesis Pharmaceuticals Business Overview
  28. 8.5.3 Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Product Portfolio
  30. 8.5.5 Sunesis Pharmaceuticals Recent Developments
  31. 8.6 Otsuka Holdings
  32. 8.6.1 Otsuka Holdings Company Information
  33. 8.6.2 Otsuka Holdings Business Overview
  34. 8.6.3 Otsuka Holdings Acute Myeloid Leukemia Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Otsuka Holdings Acute Myeloid Leukemia Drugs Product Portfolio
  36. 8.6.5 Otsuka Holdings Recent Developments
  37. 8.7 Genzyme Corporation
  38. 8.7.1 Genzyme Corporation Company Information
  39. 8.7.2 Genzyme Corporation Business Overview
  40. 8.7.3 Genzyme Corporation Acute Myeloid Leukemia Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Genzyme Corporation Acute Myeloid Leukemia Drugs Product Portfolio
  42. 8.7.5 Genzyme Corporation Recent Developments
  43. 8.8 Clavis Pharma
  44. 8.8.1 Clavis Pharma Company Information
  45. 8.8.2 Clavis Pharma Business Overview
  46. 8.8.3 Clavis Pharma Acute Myeloid Leukemia Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Clavis Pharma Acute Myeloid Leukemia Drugs Product Portfolio
  48. 8.8.5 Clavis Pharma Recent Developments
  49. 8.9 Cephalon
  50. 8.9.1 Cephalon Company Information
  51. 8.9.2 Cephalon Business Overview
  52. 8.9.3 Cephalon Acute Myeloid Leukemia Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Cephalon Acute Myeloid Leukemia Drugs Product Portfolio
  54. 8.9.5 Cephalon Recent Developments
  55. 8.10 Bristol Myers Squibb
  56. 8.10.1 Bristol Myers Squibb Company Information
  57. 8.10.2 Bristol Myers Squibb Business Overview
  58. 8.10.3 Bristol Myers Squibb Acute Myeloid Leukemia Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Bristol Myers Squibb Acute Myeloid Leukemia Drugs Product Portfolio
  60. 8.10.5 Bristol Myers Squibb Recent Developments
  61. 8.11 Ambit Biosciences Corporation
  62. 8.11.1 Ambit Biosciences Corporation Company Information
  63. 8.11.2 Ambit Biosciences Corporation Business Overview
  64. 8.11.3 Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Product Portfolio
  66. 8.11.5 Ambit Biosciences Corporation Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Acute Myeloid Leukemia Drugs Value Chain Analysis
  2. 9.1.1 Acute Myeloid Leukemia Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Acute Myeloid Leukemia Drugs Sales Mode & Process
  6. 9.2 Acute Myeloid Leukemia Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Acute Myeloid Leukemia Drugs Distributors
  9. 9.2.3 Acute Myeloid Leukemia Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst